These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX). Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596 [TBL] [Abstract][Full Text] [Related]
4. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ; Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095 [TBL] [Abstract][Full Text] [Related]
6. Influence of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Kanadani TCM; Dos Reis Veloso CE; Dorairaj S; Nehemy MB Ophthalmic Res; 2017; 58(1):18-26. PubMed ID: 28301850 [TBL] [Abstract][Full Text] [Related]
7. Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related Macular Degeneration. Lee KH; Chin HS; Kim NR; Moon YS Korean J Ophthalmol; 2015 Dec; 29(6):396-403. PubMed ID: 26635456 [TBL] [Abstract][Full Text] [Related]
8. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Mayr-Sponer U; Waldstein SM; Kundi M; Ritter M; Golbaz I; Heiling U; Papp A; Simader C; Schmidt-Erfurth U Ophthalmology; 2013 Dec; 120(12):2620-2629. PubMed ID: 23870300 [TBL] [Abstract][Full Text] [Related]
9. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E; Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Altaweel MM; Daniel E; Martin DF; Mittra RA; Grunwald JE; Lai MM; Melamud A; Morse LS; Huang J; Ferris FL; Fine SL; Maguire MG; ; Ophthalmology; 2015 Feb; 122(2):391-398.e5. PubMed ID: 25307130 [TBL] [Abstract][Full Text] [Related]
11. Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration: A MOOSE-compliant meta-analysis. Gao M; Liu L; Liang X; Yu Y; Liu X; Liu W Medicine (Baltimore); 2017 Dec; 96(50):e9345. PubMed ID: 29390407 [TBL] [Abstract][Full Text] [Related]
12. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG; Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282 [TBL] [Abstract][Full Text] [Related]
13. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Lee SJ; Koh HJ Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805 [TBL] [Abstract][Full Text] [Related]
14. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW Retina; 2013; 33(10):2126-32. PubMed ID: 23609123 [TBL] [Abstract][Full Text] [Related]
15. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. ; Maguire MG; Martin DF; Ying GS; Jaffe GJ; Daniel E; Grunwald JE; Toth CA; Ferris FL; Fine SL Ophthalmology; 2016 Aug; 123(8):1751-1761. PubMed ID: 27156698 [TBL] [Abstract][Full Text] [Related]
16. Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration. Nomura Y; Takahashi H; Tan X; Fujimura S; Obata R; Yanagi Y Jpn J Ophthalmol; 2014 Sep; 58(5):443-7. PubMed ID: 25096269 [TBL] [Abstract][Full Text] [Related]
17. The prevalence of vitreomacular adhesion in eyes with macular oedema secondary to retinal vein occlusion selected for intravitreal injections. Maggio E; Maraone G; Mete M; Vingolo EM; Grenga PL; Guerriero M; Pertile G Acta Ophthalmol; 2021 Nov; 99(7):e1154-e1161. PubMed ID: 33421346 [TBL] [Abstract][Full Text] [Related]
18. Gas-mediated vitreomacular adhesion release with intravitral ranibizumab injections for exudative age-related macular degeneration. Kang HM; Lee SJ; Kim CG; Chung EJ; Koh HJ Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1681-92. PubMed ID: 26743753 [TBL] [Abstract][Full Text] [Related]
19. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Daniel E; Shaffer J; Ying GS; Grunwald JE; Martin DF; Jaffe GJ; Maguire MG; Ophthalmology; 2016 Mar; 123(3):609-16. PubMed ID: 26681392 [TBL] [Abstract][Full Text] [Related]
20. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Brown DM; Chen E; Mariani A; Major JC; Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]